Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database
leading to pneumonitis with a poor prognosis. Tocilizumab, a type of humanized monoclonal antibody antagonizing interleukin-6 receptors, is currently utilized to treat COVID-19. The present study reviews tocilizumab adverse drug events (ADEs) reported in the World Health Organization (WHO) pharmacov...
Saved in:
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English English |
Published: |
Taylor & Francis
2021
|
Subjects: | |
Online Access: | http://irep.iium.edu.my/93893/7/93893_Tocilizumab%20in%20COVID-19%20a%20study%20of%20adverse%20drug_SCOPUS.pdf http://irep.iium.edu.my/93893/8/93893_Tocilizumab%20in%20COVID-19%20a%20study%20of%20adverse%20drug.pdf http://irep.iium.edu.my/93893/ https://www.tandfonline.com/toc/ieds20/current https://doi.org/10.1080/14740338.2021.1946513 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
my.iium.irep.93893 |
---|---|
record_format |
dspace |
spelling |
my.iium.irep.938932022-06-30T02:25:16Z http://irep.iium.edu.my/93893/ Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database Charan, Jaykaran Dutta, Siddhartha Kaur, Rimplejeet Bhardwaj, Pankaj Sharma, Parveen Ambwani, Sneha Jahan, Iffat Abubakar, Abdullahi Rabiu Islam, Salequl Hardcastle, Timothy Craig A. Rahman, Nor Azlina Lugova, Halyna Haque, Mainul RS403 Materia Medica-Pharmaceutical Chemistry leading to pneumonitis with a poor prognosis. Tocilizumab, a type of humanized monoclonal antibody antagonizing interleukin-6 receptors, is currently utilized to treat COVID-19. The present study reviews tocilizumab adverse drug events (ADEs) reported in the World Health Organization (WHO) pharmacovigilance database. Research design and methods: All suspected ADEs associated with tocilizumab between April to August 2020 were analyzed based on COVID-19 patients’ demographic and clinical variables, and severity of involvement of organ system. Results: A total of 1005 ADEs were reported among 513 recipients. The majority of the ADEs (46.26%) were reported from 18–64 years, were males and reported spontaneously. Around 80%, 20%, and 64% were serious, fatal, and administered intravenously, respectively. ‘Injury, Poisoning, and Procedural Complications’ remain as highest (35%) among categorized ADEs. Neutropenia, hypofibrinogenemia were common hematological ADEs. The above 64 years was found to have significantly lower odds than of below 45 years. In comparison, those in the European Region have substantially higher odds compared to the Region of Americas. Conclusion: Neutropenia, superinfections, reactivation of latent infections, hepatitis, and cardiac abnormalities were common ADEs observed that necessitate proper monitoring and reporting. Taylor & Francis 2021-06-28 Article PeerReviewed application/pdf en http://irep.iium.edu.my/93893/7/93893_Tocilizumab%20in%20COVID-19%20a%20study%20of%20adverse%20drug_SCOPUS.pdf application/pdf en http://irep.iium.edu.my/93893/8/93893_Tocilizumab%20in%20COVID-19%20a%20study%20of%20adverse%20drug.pdf Charan, Jaykaran and Dutta, Siddhartha and Kaur, Rimplejeet and Bhardwaj, Pankaj and Sharma, Parveen and Ambwani, Sneha and Jahan, Iffat and Abubakar, Abdullahi Rabiu and Islam, Salequl and Hardcastle, Timothy Craig and A. Rahman, Nor Azlina and Lugova, Halyna and Haque, Mainul (2021) Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database. Expert Opinion On Drug Safety, 20 (9). pp. 1125-1136. ISSN 1474-0338 E-ISSN 1744-764X https://www.tandfonline.com/toc/ieds20/current https://doi.org/10.1080/14740338.2021.1946513 |
institution |
Universiti Islam Antarabangsa Malaysia |
building |
IIUM Library |
collection |
Institutional Repository |
continent |
Asia |
country |
Malaysia |
content_provider |
International Islamic University Malaysia |
content_source |
IIUM Repository (IREP) |
url_provider |
http://irep.iium.edu.my/ |
language |
English English |
topic |
RS403 Materia Medica-Pharmaceutical Chemistry |
spellingShingle |
RS403 Materia Medica-Pharmaceutical Chemistry Charan, Jaykaran Dutta, Siddhartha Kaur, Rimplejeet Bhardwaj, Pankaj Sharma, Parveen Ambwani, Sneha Jahan, Iffat Abubakar, Abdullahi Rabiu Islam, Salequl Hardcastle, Timothy Craig A. Rahman, Nor Azlina Lugova, Halyna Haque, Mainul Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database |
description |
leading to pneumonitis with a poor prognosis. Tocilizumab, a type of humanized monoclonal antibody antagonizing interleukin-6 receptors, is currently utilized to treat COVID-19. The present study reviews tocilizumab adverse drug events (ADEs) reported in the World Health Organization (WHO) pharmacovigilance database.
Research design and methods: All suspected ADEs associated with tocilizumab between April to August 2020 were analyzed based on COVID-19 patients’ demographic and clinical variables, and severity of involvement of organ system.
Results: A total of 1005 ADEs were reported among 513 recipients. The majority of the ADEs (46.26%) were reported from 18–64 years, were males and reported spontaneously. Around 80%, 20%, and 64% were serious, fatal, and administered intravenously, respectively. ‘Injury, Poisoning, and Procedural Complications’ remain as highest (35%) among categorized ADEs. Neutropenia, hypofibrinogenemia were common hematological ADEs. The above 64 years was found to have significantly lower odds than of below 45 years. In comparison, those in the European Region have substantially higher odds compared to the Region of Americas.
Conclusion: Neutropenia, superinfections, reactivation of latent infections, hepatitis, and cardiac abnormalities were common ADEs observed that necessitate proper monitoring and reporting. |
format |
Article |
author |
Charan, Jaykaran Dutta, Siddhartha Kaur, Rimplejeet Bhardwaj, Pankaj Sharma, Parveen Ambwani, Sneha Jahan, Iffat Abubakar, Abdullahi Rabiu Islam, Salequl Hardcastle, Timothy Craig A. Rahman, Nor Azlina Lugova, Halyna Haque, Mainul |
author_facet |
Charan, Jaykaran Dutta, Siddhartha Kaur, Rimplejeet Bhardwaj, Pankaj Sharma, Parveen Ambwani, Sneha Jahan, Iffat Abubakar, Abdullahi Rabiu Islam, Salequl Hardcastle, Timothy Craig A. Rahman, Nor Azlina Lugova, Halyna Haque, Mainul |
author_sort |
Charan, Jaykaran |
title |
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database |
title_short |
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database |
title_full |
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database |
title_fullStr |
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database |
title_full_unstemmed |
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database |
title_sort |
tocilizumab in covid-19: a study of adverse drug events reported in the who database |
publisher |
Taylor & Francis |
publishDate |
2021 |
url |
http://irep.iium.edu.my/93893/7/93893_Tocilizumab%20in%20COVID-19%20a%20study%20of%20adverse%20drug_SCOPUS.pdf http://irep.iium.edu.my/93893/8/93893_Tocilizumab%20in%20COVID-19%20a%20study%20of%20adverse%20drug.pdf http://irep.iium.edu.my/93893/ https://www.tandfonline.com/toc/ieds20/current https://doi.org/10.1080/14740338.2021.1946513 |
_version_ |
1738510112516997120 |
score |
13.160551 |